Hikma announces FDA approval and launch of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase

Product

Hikma announces FDA approval and launch of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase

London, 31 May 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces the approval of Fluticasone 50 MCG Spray, the store brand equivalent of Flonase®, by the U.S. Food and Drug Administration (FDA).

Flonase® (fluticasone propionate nasal spray USP, 50 mcg per spray) is indicated for the temporary relief of hay fever or other upper respiratory allergies in adult and paediatric patients 4 years of age and older. Combined generic and branded sales for the twelve months ending May 2016 were $343 million.

Hikma, through its wholly-owned subsidiary West-Ward Pharmaceuticals, has partnered with Perrigo Company plc, a leading supplier of over-the-counter (OTC) products, for the launch of this product in the OTC market. Perrigo expects to begin customer shipments immediately.

Michael Raya, Chief Executive of West-Ward Pharmaceuticals, said:

“We are very pleased to be working with Perrigo to improve access to this important product for consumers interested in purchasing fluticasone propionate nasal spray over-the- counter.”